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ABSTRACT 
Objective: The main aim of the present investigation was to develop sustained release microbeads of ritonavir that has a shorter half-life (3-5 h) 
and requires twice a day administration. These formulations exhibit a sustained release of ritonavir that would expect to improve the therapy, 
better drug utilization, and patient compliance. 
Methods: Gellan-chitosan and calcium chloride reinforced beads of ritonavir were prepared by ionotropic gelation method employing different 
concentrations of gellan, chitosan, calcium chloride and drug. The prepared beads were evaluated for various physicochemical parameters such as 
particle size determination, drug entrapment efficiency, swelling studies, infrared spectroscopy study, differential scanning calorimetry, x-ray 
diffraction analysis, scanning electron microscopy, in vitro drug release study and in vivo bioavailability studies.  
Results: From the results, formulation GC-II exhibited higher drug entrapment efficiency (79.65±0.012), higher swelling index, sustained drug 
release over a period of 24 h, increased oral bioavailability (2.07 times higher than that of pure drug) and decreased elimination rate (2.15 times 
lesser for ritonavir microbeads) with prolonged elimination half-life (2.15 times more than pure drug) as compared to pure drug. 
Conclusion: Ritonavir microbeads have demonstrated as a better delivery system for the sustained release of the drug; which may in turn 
circumvent the drawbacks associated with the conventional therapy. 
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Developing a sustained release drug delivery system is an approach 
that offers a uniform concentration of drug available at the site of 
absorption. Due to this unique property, the system maintains an 
adequate plasma concentration in the therapeutic range [1]. During 
the past few decades, a great effort has been contributed for the 
development of novel drug delivery systems, which ensures the 
targeting of drug to a particular site and maintaining the required 
concentration to exhibit better pharmacological response [2]. In 
most of the incidences, the optimal therapeutic response is observed 
when adequate blood levels are maintained with minimal variation. 
Sustained release formulations are gained importance for the oral 
administration of drug owing to their more consistent blood levels. 
Polymeric beads are particulate carriers in which the drug is 
dispersed in solution or crystalline form that facilitates the 
sustained release profile of the drug moiety incorporated into it [3]. 
Among them the microencapsulation technology facilitates an 
effective administration of drugs by improving their solubility, 
minimizing side effects and improving therapeutic response [4]. It is 
desired that an improved therapeutic efficacy coupled with the 
reduced adverse effect is considered to be the most significant 
aspects in future research work [5]. The application of natural 
biodegradable polymers in sustained drug delivery still continues to 
be of great research area owing to their abundant availability, the 
capability to undergo any chemical modification and compatibility 
[6-7]. Ritonavir, a protease inhibitor approved by USFDA in 1996 for 
the treatment of HIV infection, has elimination half-life was reported 
to be in the range of 3-5 h [8]. Ritonavir is administered 300 mg 
twice daily regimen. Converting a twice a day administration into 
once a day could facilitate the effectiveness in the anti-HIV therapy, 
better drug utilization and better patient compliance. Therefore, the 
main purpose of this study was to formulate and evaluate ritonavir 
microbeads for ritonavir by ionotropic gelation method, so as to 
improve the sustained release of the drug. Various parameters such 
as particle size determination, drug entrapment efficiency, swelling 
studies, infrared spectroscopy study, differential scanning 
calorimetry, x-ray diffraction analysis, scanning electron 
microscopy, in vitro drug release study and in vivo bioavailability 
studies were systematically investigated. 
MATERIALS AND METHODS 
Materials 
Ritonavir was obtained as a gift from Dr. Reddy’s Lab (Hyderabad, India). 
Gellan gum was purchased from Sigma-Aldrich Ltd, (Mumbai, India) and 
chitosan were procured from Sigma-Aldrich Ltd, (Mumbai, India). All 
other chemicals used were of pharmaceutical or analytical grade.  
Preparation of ritonavir microbeads 
The beads were prepared by ionotropic gelation technique. Initially, 
gellan gum solution was prepared by dissolving gellan in deionized 
water and followed by heating at 60 °. About 50 ml of the gellan gel from 
each batch was taken separately and a different concentration of drug 
was dispersed uniformly in the gel maintained at 40 ° with continuous 
stirring. The stirring was further continued until uniform dispersion of 
drug was achieved. The resultant homogenous slurry was dropped in to 
a 50 ml solution containing different concentrations of calcium chloride 
and chitosan, using a syringe (21G) under stirring condition. The stirring 
was continued for certain period of time to improve the mechanical 
strength of the beads and also to prevent aggregation. The formed beads 
were separated from the solution by filtration and dried at 40 °. The 
gellan beads with the exception of chitosan were also prepared using 
aforesaid procedure [9]. The details of the composition of microbeads, 
particle size and drug encapsulation efficiency of different formulations 
were shown in table 1. 
Particle size determination 
The particle size of the beads was measured using a micrometer 
(Mitotuyo, Japan). The average diameter of 100 particles per batch 
was estimated [9]. 
Drug entrapment efficiency (DEE) 
The drug content in the beads was estimated by digestion method, 
where a known quantity of ritonavir loaded beads (20 mg) were 
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pulverized in a glass mortar with pestle and incubated in 0.1 N HCl at 
room temperature for 2 h to extract the drug completely. The clear 
supernatant solution was assayed spectrophotometrically for drug 
content at the wavelength of 245 nm. Supernatant from the empty 
beads was taken as blank. All samples were analyzed triplicate [9].  
Swelling studies  
The swelling properties of the beads were determined my mass 
measurement. Samples of beads of known weight (25 mg) were 
incubated with 25 ml of swelling solution (0.1 N HCl) and allowed to 
swell at 37 ° C. The swollen beads were then removed periodically, an 
excess swelling solution was wiped using a dry filter paper and their 
final weight was determined using an electronic balance. The 
percentage swelling of the beads was calculated using the formula [9]. 
 …. (1) 
Infra red spectroscopy study (FTIR) 
Infrared spectra of ritonavir, blank gellan and chitosan microbeads 
and drug loaded beads were obtained in KBr pellets using a FTIR 
spectrophotometer (Perkin-Elmer, Japan). The samples were 
scanned between in the range of 4000 to 400 cm-1.  
Differential scanning calorimetric analysis (DSC) 
DSC analysis was undertaken to observe the changes if any during 
the preparation of beads. DSC of ritonavir, blank gellan and chitosan 
microbeads and drug loaded beads were examined by using a 
thermal analyzer (TA instruments, Bangalore). The samples were 
heated from 40-200 ° at a heating rate of 10 ° C/min under constant 
purging of nitrogen at a flow rate of 50 ml/min respectively.  
X-ray diffraction analysis (XRD) 
X-ray powder diffraction analysis of ritonavir, drug loaded beads 
were carried out using the X-ray diffractometer (Jeol JDX 8030 X-ray 
diffractometer Tokyo, Japan) using Ni-filtered, CuKα radiation, a 
voltage of 40 kV and a 25-mA current. The scanning rate employed 
was 1 °/min and scanned over 2θ range of the 10 to 80 °. 
Scanning electron microscopy (SEM)  
The surface morphology of the beads was investigated using scanning 
electron microscope (Jeol, JSM, 35CF, Japan). The beads were mounted 
onto individual stab and then coated with carbon and gold (100 and 
50 Å thickness respectively). The coated samples were then observed 
under scanning electron microscope operated at 7KV. 
In vitro drug release study 
In vitro drug release studies of ritonavir from beads were carried out 
using 0.1 N HCl (500 ml) USP paddle type dissolution apparatus 
(USP XXIII, Electrolab, Mumbai) at 50 rpm. A weighed quantity of 
beads equivalent to 50 mg was used in each test. At predetermined 
time intervals a 5 ml of samples were withdrawn and same volume 
of fresh media was replaced. The amount of drug release was 
analyzed at 245 nm after proper dilution if required.  
Release kinetics 
Different kinetic equations (zero order, first order and Higuchi’s 
equations) were applied to interpret the release rate of the drug 
from the matrix system. The best fit with higher correlation 
(r2>0.98) was found with Higuchi’s equation for all the formulations. 
Two factors, however, diminish the applicability of Higuchi’s 
equation to matrix systems [10]. This model fails to allow for the 
influence of swelling of the matrix (upon hydration) and gradual 
erosion of the matrix. Therefore, the dissolution data were also fitted 
to the well-known exponential Koresmeyer–Peppa’s equation [11]. 
(2) 
Mt/Mα is the fraction of drug release at time ‘t’, ‘k’ is the kinetic 
constant and ‘n’ is the release exponent (indicating release 
mechanism). In addition, for determination of the exponent ‘n’, one 
must use only the initial portion of the release cure (Mt/Mα<0.6) 
[11]. Ritger and Peppa’s have defined the exponent ‘n’ as a function 
of the aspect ratio (2a/l) defined as the ratio of diameter (2a) to 
thickness (l). For tablets, depending on the aspect ratios, ‘n’ values 
between 0.43 and 0.5 indicates fickian (case I) diffusion mediated 
release, non-fickian (anomalous) release, coupled diffusion and 
polymer matrix relaxation occurs if 0.5<n<0.89, purely matrix 
relaxation or erosion-mediated release occurs for n=1 (zero order 
kinetics) and super case II type of release occurs for n>0.89 [12].  
Bioavailability studies 
Albino Wister rats (male) weighing 200±50 g were used for the oral 
bioavailability studies [13]. The protocol of the study was approved 
by the institutional animal ethics committee (JSSCP/IAEC/M. 
PHARM/PH. CEUTICS/01/2014-15 dated 10/10/2014). The animals 
were divided into three groups of six animals each. Group I served as 
control, group II pure drug in suspension form at a dose of 7.5 mg 
and group III received microbeads containing drug of 15 mg by oral 
administration. A randomized, two treatments, two period, two 
sequence, single dose cross over bioavailability study was carried 
out for the formulations in order to prove the safety and efficacy of 
the formulations. Prior to the study, the animals were kept under 
fasting condition and free access for water ad libitum. 0.5 ml of blood 
was withdrawn from the marginal ear vein of the animals at the 
predetermined time intervals of 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 
hour using a sterilized disposable syringe. The blood sample were 
collected in a ria vial containing the anticoagulant (1 ml of 11% 
sodium citrate) were centrifuged at 4000 rpm for 4 min to separate 
plasma. The plasma samples were deprotinised using an equal 
volume of 10% perchloric acid and vortexed for 2 min. It was further 
centrifuged at 4000 rpm for 4 min and the supernatant liquid was 
separated. A reproducible analytical technique was developed for 
the estimation of the drug in the plasma samples. The HPLC 
optimized chromatographic conditions consisted of a stationary 
phase Hiber C18 (250×4.6 mm i.d., 5µ), mobile phase acetonitrile: 
methanol: phosphate buffer (PH 5.8) in the ratio of 50:20:30, with a 
flow rate of 1 ml/min with a sample volume of 20 µl. The detection 
was performed at 245 nm using Shimadzu HPLC: Model LC-2010 A-
HT auto sampler. Darunavir was used as an internal standard. 
Various pharmacokinetic parameters such as Cmax, Tmax, t½, Kel, AUCo-t 
and AUCo-α were estimated using PK1 and PK2 solutions software. 
Statistical analysis 
Statistical analysis was performed using SPSS version 13.0. The 
pharmacokinetic parameters like Cmax, Tmax, t½, Kel, AUCo-t and AUCo-α 
of the both the formulations are presented in mean±SD One way 
ANOVA (analysis of variance) was employed in the statistical 
analysis of the determined parameters in this study. Statistical 
significance was defined at p<0.05. 
RESULTS AND DISCUSSION 
Particle size determination  
The microbeads were found to be smooth and free flowing in nature. 
The average particle size of the different batches of the formulation 
was varied from 624±2.32 to 802±2.21 µm. This revealed that as the 
quantity of gellan increases the sizes of the beads also increases due 
to the increase in the microviscosity of the polymer. 
Drug entrapment efficiency (DEE) 
The DEE was found to be in the range of 46.35±0.017% to 
79.65±0.012%. These results indicated that the DEE of beads 
increases with an increase in the concentration of the polymer. This 
could be explained by the fact that the ionized state of the polymer 
at a higher concentration enables intense cross-linking results in 
higher encapsulation efficiency of drug. While increasing the 
concentration of the drug resulted in decrease in encapsulation 
efficiency. Formulations containing chitosan exhibited higher 
encapsulation efficiency than the formulations not containing 
chitosan. 
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Drug entrapment efficiency 
(DEE)% ** 
GC-I 50 50 50 2 748±3.2 58.4±0.034 
GC–II 50 100 50 2 792±3.1 79.65±0.012 
GC–III 100 50 50 2 802±2.2 65.5±0.033 
GC–IV 50 50 50 4 660±2.3 58.1±0.012 
GC–V 50 100 50 4 679±3.6 77.02±0.026 
GC–VI 100 50 50 4 703±2.6 63.05±0.012 
GC–VII 50 50 - 2 624±2.3 46.32±0.017 
GC-VIII 50 100 - 2 651±2.6 58.21±0.013 
GC-IX 100 50 - 2 734±3.6 47.89±0.052 
 *(mean±SD, n=100), **(mean±SD, n=3) 
 
Swelling studies  
In order to evaluate the swelling ability of beads at different pH 
conditions, the cross-linked beads exhibited higher degree of swelling at 
acidic pH (0.1 N HCl) than the alkaline pH (7.4) as shown in fig. 1 and 2. 
The increase in swelling at acidic pH is mainly due to the protonation of 
chitosan; whereas decrease in swelling at alkaline pH is due to the 
ionization of carboxyl group in the gellan as inner layer in beads. The 
rate of swelling is also governed by the concentration of the polymer and 
strength of calcium chloride solution used. Swelling of beads decreased 
with increased concentration of gellan in the gelling solution and 
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Fig. 2: Swelling studies of ritonavir microbeads in phosphate buffer (PH 7.4), (mean±SD, n=3) 
Fourier transform infra red spectroscopy study (FTIR) 
The infrared spectra of drug, blank gellan and chitosan microbeads 
and drug loaded beads are shown in fig. 3-5. These spectra’s revealed 
that no shifting of peaks was observed, indicating the stability of the 
drug during the encapsulation process. The principle peaks of 
ritonavir, N-H at 3328.28 cm-1, Ar-H at 3041.84 cm-1, CH-stretching 
2868.24 cm-1, C=N at 1455.34 cm-1 and O-H at 3507.67 cm-1. After 
interpretation through the above spectra with the drug loaded MB, it 
was confirmed that there was no major shifting as well as no loss of 
functional peaks. From the spectra it was concluded that the polymer 
gellan gum and chitosan is found to be compatible in entrapping the 
drug. The decrease in the peak intensity of the formulation may be 
attributed to the fine dispersion of drug in the polymer matrix. 
 
 
Fig. 3: Fourier transform Infra red spectroscopy study (FTIR) of ritonavir 
 
 
Fig. 4: Fourier transform infra red spectroscopy study (FTIR) of blank gellan and chitosan microbeads 
 
Differential scanning calorimetry analysis (DSC) 
Fig. 6-8 illustrates the comparative DSC Thermogram of Rt, gellan-
chitosan bead, Rt loaded gellan-chitosan bead. The DSC Thermogram 
of Rt showed a sharp endothermic peak corresponding to melting of 
crystalline at 125.46 °C. The sharp endothermic peak of drug in 
loaded beads has not appeared indicating that the drug was 
dispersed in an amorphous state in the polymer. 
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Fig. 5: Fourier Transform Infra red spectroscopy study (FTIR) ritonavir loaded microbeads 
 
 
Fig. 6: Differential scanning calorimetry of ritonavir 
 
 
Fig. 7: Differential scanning calorimetry of gellan-chitosan beads 
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Fig. 8: Differential scanning calorimetry of ritonavir microbeads 
 
 
Fig. 9: X-ray diffraction analysis of ritonavir 
 
 
Fig. 10: X-ray diffraction analysis of ritonavir microbeads 
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X-ray diffraction analysis (XRD) 
The X-ray powder diffraction patterns of drug and drug-loaded 
formulation are compared. The X-ray powder diffraction pattern of 
pure drug showed its own crystal peaks between 2θ of 10 ° and 80 °. 
It was observed that the characteristic peaks of drug were found to 
be absent in the drug entrapped gellan-chitosan beads indicates the 
probable decrease in the crystallinity of drug. The undefined, broad, 
diffused peaks with the low intensities for drug entrapped beads 
revealed that the conversion of drug from crystalline to amorphous 
form in the formulation fig. 9-10. 
Scanning electron microscopy (SEM)  
The SEM of the drug loaded beads was found to be irregular in shape 
having smooth and dense surface with inward dent and shrinkage 
due to collapse of the wall during dehydration. The fibrous network 
was also observed on the surface of the beads as shown in fig. 11-13. 
 
 
Fig. 11: Scanning electron microscopy (SEM) of ritonavir microbeads 
 
 
Fig. 12: Scanning electron microscopy (SEM) of ritonavir microbeads with dense surface 
 
 
Fig. 13: Scanning electron microscopy (SEM) of ritonavir microbeads with fibrous network 
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In vitro drug release study 
The in vitro release profile of drug loaded beads was depicted in 
fig. 14. From the results it can be observed that the drug release 
from the beads significantly decreased with an increase in the 
concentration of the polymer. This could be explained as an 
increase in the concentration of polymer substantially increases 
the density of the matrix and diffusional path in which allows the 
drug molecules have to traverse. A biphasic pattern of drug release 
was observed with initial burst effect followed by the sustained 
release due to the process of gelation as a result of cross linking, 
which is a characteristic feature of matrix diffusion. It was 
observed that the initial burst effect of drug was substantially 
decreased in case of beads coated with chitosan over non-coated 
beads. The fact could be due to the coating of chitosan exhibited 
better incorporation efficiency and offered a thick coating over the 
beads. This could be resulted in the decrease burst effect of drug 






































Fig. 14: In vitro release profiles of ritonavir from microbeads (n-3±SD) 
 
Release kinetics 
In order to elucidate the mechanism of drug release, the data were 
fitted into various models such as zero order, first order, Higuchi 
and Koresmeyar Peppa’s. The data’s are shown in table 2. The 
examination of the co efficient of correlation (r2) values indicated 
that the prepared beads followed first order kinetics with non 
fickian diffusion mechanism of drug release. 
 
Table 2: Regression coefficient (r2) of ritonavir data from studied matrices according to different kinetic models, diffusion exponent (n) of 
Peppa’s model 
Code of formulation Zero order (r2) First order (r2) Higuchi (r2) Peppa’s 
n (r2) 
GC-I 0.75 0.972 0.92 0.62 0.91 
GC–II 0.81 0.961 0.91 0.67 0.92 
GC–III 0.76 0.971 0.97 0.61 0.97 
GC–IV 0.79 0.959 0.96 0.6 0.94 
GC–V 0.81 0.947 0.95 0.68 0.95 
GC–VI 0.7 0.978 0.94 0.69 0.96 
GC–VII 0.82 0.981 0.97 0.61 0.97 
GC-VIII 0.85 0.94 0.93 0.71 0.92 
GC-IX 0.81 0.97 0.97 0.81 0.94 
 
Bioavailability studies 
The relative bioavailability of the developed ritonavir microbeads 
(CG-2) was compared with drug in suspension form. The ritonavir 
microbeads produced a plasma concentration time profile typical of 
the prolonged dissolution characteristic of a SR formulation as 
evident from fig. 15 and table 3. The Rt MB demonstrated a longer 
time to reach a peak concentration than the pure drug in suspension 
form and appeared to be more consistent in overall performance. 
This was indicated by lower variation in plasma concentrations, 
longer time to peak plasma concentration. There was a significant 
difference in the extent of absorption as assessed by measurements 
of AUCo-t. However, AUCo-α value for the ritonavir microbeads was 
2.07 times higher than that of pure drug. The ritonavir microbeads 
indicated more efficient and sustained drug delivery, which would 
maintain plasma levels better. This was also evident by the lower 
elimination rate (Kel) (2.15 times lesser for ritonavir in microbeads) 
and higher t½ values (2.15 times more than pure drug). The 
pharmacokinetic parameters of the two different formulations of 
ritonavir were compared statistically by one way ANOVA (analysis 
of variance) using SPSS version 13.0. The pharmacokinetic 
parameters such as Cmax, Tmax, t½, Kel, AUCo-t and AUCo-α of the pure 
drug and Rt MB were found to be significantly different (p<0.05) by 
one way ANOVA. 
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Table 3: Pharmacokinetic profile of ritonavir (pure drug) and ritonavir loaded microbeads (mean±SD, n=6) 
Pharmacokinetic parameters Type of formulations 
Ritonavir Ritonavir loaded microbeads 
Cmax (ng/ml) 0.272±0.045 0.248±0.0432.72 
Tmax(h) 4±0.5 6±1.2 ‡ 
AUCo-t(ng. h/ml) 1.565±0.42 3.171±0.22 ‡ 
T1/2 (h) 2.54±0.16 5.46±0.12 ‡ 
Kel (h-1) 0.2728±0.003 0.1268±0.005† 
AUC0-α(ng. h/ml) 1.641±0.012 8.83 3.3916±0.015 ‡ 
‡ Signi\icantly higher than pure drug (p<0.05), † Signi\icantly lower than IR pure drug (p<0.05) 
 
 
Fig. 15: Mean plasma concentration of ritonavir and ritonavir microbeads, (mean±SD, n=6) 
 
CONCLUSION 
Ritonavir microbeads were successfully prepared using ionotropic 
gelation method with good entrapment efficiency. A change in the 
drug crystallinity during the formulation was revealed by DSC and 
XRD study. FTIR spectral study revealed no chemical change in the 
microbeads formulation. The microbeads exhibited higher drug 
entrapment efficiency, higher swelling index, sustained drug release, 
increased oral bioavailability and decreased elimination rate with 
prolonged elimination half-life as compared to pure drug. The 
present investigation demonstrated microbeads as a potential drug 
delivery system for improving the oral bioavailability of ritonavir. 
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